Intellia has identified a genetic risk factor associated with elevated liver enzymes in patients receiving its CRISPR gene-editing therapy for ATTR amyloidosis. The company said the finding came from analyzing patients who experienced the highest post-treatment liver enzyme elevations. The update matters for CRISPR programs because liver enzyme increases are among the most closely watched safety signals for in vivo genome editing, and risk stratification can influence monitoring and patient selection. Intellia’s disclosure suggests the company is moving beyond safety observation toward mechanistic or genomic predictors. Further details were not included in the provided summary, but the statement underscores the growing use of genetics to explain variability in gene-editing tolerability across treated populations.